^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
trastuzumab rezetecan (SHR-A1811)
i
Other names: SHR-A1811
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Jiangsu Hengrui Pharma
Drug class:
Topoisomerase I inhibitor, HER2-targeted antibody-drug conjugate
Related drugs:
1m
SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in ER Positive/HER2 Low Breast Cancer (clinicaltrials.gov)
P2, N=93, Not yet recruiting, Shengjing Hospital
New P2 trial • Combination therapy
|
trastuzumab rezetecan (SHR-A1811) • adebrelimab (SHR-1316)
2ms
A Phase 1 Study of SHR-A1811 in Patients With Selected HER2 Expressing Tumors (clinicaltrials.gov)
P1, N=101, Active, not recruiting, Jiangsu HengRui Medicine Co., Ltd. | Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Jun 2023 --> Jun 2024
Enrollment closed • Trial completion date • Trial primary completion date • Metastases
|
trastuzumab rezetecan (SHR-A1811)
2ms
A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing (clinicaltrials.gov)
P2, N=88, Recruiting, Fudan University | N=66 --> 88
Enrollment change • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • AR (Androgen receptor)
|
HER-2 positive • HER-2 amplification • HER-2 mutation • AR positive
|
trastuzumab rezetecan (SHR-A1811) • leuprolide acetate for depot suspension • Airui'en (rezvilutamide) • SHR-A1921
2ms
SHR-A1811-309: Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan (clinicaltrials.gov)
P3, N=120, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
Stivarga (regorafenib) • oxaliplatin • irinotecan • Fruzaqla (fruquintinib) • trastuzumab rezetecan (SHR-A1811) • Lonsurf (trifluridine/tipiracil)
3ms
A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors. (clinicaltrials.gov)
P1/2, N=364, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 expression
|
Irene (pyrotinib) • trastuzumab rezetecan (SHR-A1811)
3ms
Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer (clinicaltrials.gov)
P1/2, N=350, Not yet recruiting, Shandong Suncadia Medicine Co., Ltd.
New P1/2 trial • Metastases
|
trastuzumab rezetecan (SHR-A1811) • SHR-A2009 • adebrelimab (SHR-1316)
4ms
SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen (clinicaltrials.gov)
P3, N=360, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
HER-2 positive • HER-2 amplification
|
paclitaxel • docetaxel • Cyramza (ramucirumab) • irinotecan • trastuzumab rezetecan (SHR-A1811)
4ms
Injection of SHR-A1811 Versus TAS-102 in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan (clinicaltrials.gov)
P3, N=96, Not yet recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd.
New P3 trial • Metastases
|
oxaliplatin • irinotecan • trastuzumab rezetecan (SHR-A1811) • Lonsurf (trifluridine/tipiracil)
5ms
A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer (clinicaltrials.gov)
P2, N=66, Recruiting, Henan Cancer Hospital | Active, not recruiting --> Recruiting
Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 expression • HER-2 underexpression
|
trastuzumab rezetecan (SHR-A1811)
6ms
A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy (clinicaltrials.gov)
P3, N=1200, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
New P3 trial
|
Kadcyla (ado-trastuzumab emtansine) • trastuzumab rezetecan (SHR-A1811)
6ms
SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen (clinicaltrials.gov)
P3, N=360, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
New P3 trial • Metastases
|
HER-2 positive • HER-2 amplification
|
paclitaxel • docetaxel • Cyramza (ramucirumab) • irinotecan • trastuzumab rezetecan (SHR-A1811)
6ms
FUSCC Refractory TNBC Platform Study (FUTURE2.0) (clinicaltrials.gov)
P2, N=120, Recruiting, Fudan University | Not yet recruiting --> Recruiting
Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • ER negative • PGR negative
|
Avastin (bevacizumab) • AiRuiKa (camrelizumab) • trastuzumab rezetecan (SHR-A1811)
7ms
Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases (clinicaltrials.gov)
P2, N=100, Recruiting, Henan Cancer Hospital | N=75 --> 100
Enrollment change • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
|
Avastin (bevacizumab) • Irene (pyrotinib) • trastuzumab rezetecan (SHR-A1811)
7ms
A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
P1/2, N=324, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open • Combination therapy • Metastases
|
Irene (pyrotinib) • trastuzumab rezetecan (SHR-A1811) • adebrelimab (SHR-1316)
7ms
A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer (clinicaltrials.gov)
P3, N=864, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
New P3 trial • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
|
Herceptin (trastuzumab) • docetaxel • Perjeta (pertuzumab) • trastuzumab rezetecan (SHR-A1811)
7ms
A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer (clinicaltrials.gov)
P2, N=66, Active, not recruiting, Henan Cancer Hospital | Not yet recruiting --> Active, not recruiting
Enrollment closed
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 expression • HER-2 underexpression
|
trastuzumab rezetecan (SHR-A1811)
9ms
A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing (clinicaltrials.gov)
P2, N=66, Recruiting, Fudan University | Not yet recruiting --> Recruiting | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2024 --> Sep 2025
Enrollment open • Trial completion date • Trial primary completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • AR (Androgen receptor)
|
HER-2 positive • HER-2 amplification • HER-2 mutation • AR positive
|
trastuzumab rezetecan (SHR-A1811) • leuprolide acetate for depot suspension • Airui'en (rezvilutamide) • SHR-A1921
9ms
A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression. (clinicaltrials.gov)
P1/2, N=116, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 expression • HER-2 underexpression
|
capecitabine • trastuzumab rezetecan (SHR-A1811)
10ms
Phase I trial of SHR-A1811 in HER2-expressing advanced gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJ) and colorectal cancer (CRC) (ESMO 2023)
Table: 684P Efficacy outcomes Conclusions SHR-A1811 showed an acceptable safety profile and promising clinical activity in pts with HER2-expressing GC/GEJ and CRC. Further investigation was warranted.
P1 data • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 expression
|
trastuzumab rezetecan (SHR-A1811)
10ms
The HER2-targeting ADC SHR-A1811 in HER2-expressing/mutated advanced non-breast solid tumors (STs): Results from the global phase I study (ESMO 2023)
Background SHR-A1811 is a novel ADC composed of trastuzumab (anti-HER2), a cleavable linker, and a topoisomerase I inhibitor payload, with optimized drug-antibody ratio of 6 and strong bystander killing effect. Table: 656MO ORR by tumor type and HER2 status BTC (N=22) UC (N=23) GC/GEJA (N=13) CRC (N=14) Other tumors (N=26) ORR*, n/N (%)(95% CI) 9/15 (60.0%)(32.3–83.7) 13/22 (59.1%)(36.4–79.3) 6/12 (50.0%)(21.1–78.9) 4/11 (36.4%)(10.9–69.2) 7/25 (28.0%)(12.1–49.4) HER2 IHC 3+ 7/10 (70.0%) (34.8–93.3) 2/6 (33.3%) (4.3–77.7) 4/10 (40.0%) (12.2–73.8) 3/3 (100.0%) (29.2–100.0) 4/8 (50.0%) (15.7–84.3) HER2 IHC 2+ 0/1 7/10 (70.0%) (34.8–93.3) 2/2 (100.0%) (15.8–100.0) 0/3 1/8 (12.5%) (0.3–52.7) HER2 IHC 1+ 1/2 (50.0%) (1.3–98.7) 4/5 (80.0%) (28.4–99.5) 0 0/1 2/6 (33.3%) (4.3–77.7) HER2 mutation and/or amplification 1/2 (50.0%) (1.3–98.7) 0/1 0 1/4 (25.0%) (0.6–80.6) 0/3 *tumor response evaluable set. Conclusions SHR-A1811 had favorable antitumor activity and acceptable safety profile in heavily pretreated HER2-expressing/mutated advanced non-breast STs, including BTC, UC, GC/GEJA, and CRC.
Clinical • P1 data • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 amplification • HER-2 mutation • HER-2 expression
|
Herceptin (trastuzumab) • trastuzumab rezetecan (SHR-A1811)
10ms
SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial (clinicaltrials.gov)
P3, N=530, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 expression
|
gemcitabine • capecitabine • albumin-bound paclitaxel • Halaven (eribulin mesylate) • trastuzumab rezetecan (SHR-A1811)
10ms
A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing (clinicaltrials.gov)
P2, N=66, Not yet recruiting, Fudan University
New P2 trial • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • AR (Androgen receptor)
|
HER-2 positive • HER-2 amplification • HER-2 mutation • AR positive
|
trastuzumab rezetecan (SHR-A1811) • leuprolide acetate for depot suspension • Airui'en (rezvilutamide) • SHR-A1921
11ms
A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer (clinicaltrials.gov)
P2, N=66, Not yet recruiting, Henan Cancer Hospital
New P2 trial
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 expression • HER-2 underexpression
|
trastuzumab rezetecan (SHR-A1811)
11ms
A Study of SHR-A1811 in Subjects With Gynaecologic Oncology (clinicaltrials.gov)
P2, N=225, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
New P2 trial
|
trastuzumab rezetecan (SHR-A1811)
12ms
A Study of SHR-A1811 in Subjects With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
P1/2, N=153, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Trial primary completion date: Jan 2023 --> May 2023
Trial primary completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 amplification • HER-2 mutation • HER-2 expression
|
trastuzumab rezetecan (SHR-A1811)
1year
A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression. (clinicaltrials.gov)
P1/2, N=116, Not yet recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd.
New P1/2 trial
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 expression • HER-2 underexpression
|
capecitabine • trastuzumab rezetecan (SHR-A1811)
1year
Different Targeted Antibody-drug Conjugates For HER2 Ultra-low or No Expression Advanced Breast Cancer（GALAXY） (clinicaltrials.gov)
P1/2, N=56, Active, not recruiting, Fudan University
New P1/2 trial • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 negative
|
trastuzumab rezetecan (SHR-A1811)
1year
Study of SHR-A1811 in HER2-positive Advanced Breast Cancer With Brain Metastases (clinicaltrials.gov)
P2, N=75, Recruiting, Henan Cancer Hospital | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
|
Avastin (bevacizumab) • Irene (pyrotinib) • trastuzumab rezetecan (SHR-A1811)
1year
SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial (clinicaltrials.gov)
P3, N=528, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
New P3 trial • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 expression
|
gemcitabine • capecitabine • albumin-bound paclitaxel • Halaven (eribulin mesylate) • trastuzumab rezetecan (SHR-A1811)
1year
Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2+ Gastric Cancer (clinicaltrials.gov)
P2, N=156, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
|
capecitabine • oxaliplatin • trastuzumab rezetecan (SHR-A1811)
1year
A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer. (clinicaltrials.gov)
P1/2, N=300, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
New P1/2 trial • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
Avastin (bevacizumab) • fulvestrant • letrozole • anastrozole • trastuzumab rezetecan (SHR-A1811) • AiRuiKang (dalpiciclib)
1year
A Study of SHR-A1811 Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients (clinicaltrials.gov)
P2, N=61, Recruiting, Shengjing Hospital | Not yet recruiting --> Recruiting | Trial completion date: Nov 2028 --> Feb 2029 | Initiation date: Nov 2022 --> Mar 2023 | Trial primary completion date: Nov 2023 --> Feb 2024
Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
|
Irene (pyrotinib) • trastuzumab rezetecan (SHR-A1811)
1year
Study of SHR-A1811 in HER2-positive Advanced Breast Cancer With Brain Metastases (clinicaltrials.gov)
P2, N=75, Not yet recruiting, Henan Cancer Hospital
New P2 trial • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
|
Avastin (bevacizumab) • Irene (pyrotinib) • trastuzumab rezetecan (SHR-A1811)
1year
Safety, tolerability, pharmacokinetics, and antitumor activity of SHR-A1811 in HER2-expressing/mutated advanced solid tumors: A global phase 1, multi-center, first-in-human study (AACR 2023)
Background: SHR-A1811 is an ADC comprised of a humanized anti-HER2 monoclonal antibody (trastuzumab), a cleavable linker, and a DNA topoisomerase I inhibitor payload. SHR-A1811 was well-tolerated and showed promising antitumor activity in heavily pretreated advanced solid tumors.Table 1. Subgroup analyses of ORRNo. of prior treatment lines in metastatic setting in all pts (N=250)HER2 positive BC (N=108)HER2-low BC (N=77)Other tumor types (N=65)≤381.8% (45/55)58.7% (27/46)36.7% (18/49)>381.1% (43/53)51.6% (16/31)31.3% (5/16)Prior anti-HER2 therapies in pts with BC (N=185)*HER2 positive BC (N=108)HER2-low BC (N=77)All BC (N=185)Any82.2% (88/107, 73.7-89.0)68.8% (11/16, 41.3-89.0)80.5% (99/123, 72.4-87.1)Trastuzumab81.9% (86/105, 73.2-88.7)75.0% (9/12, 42.8-94.5)81.2% (95/117, 72.9-87.8)Pertuzumab83.0% (39/47, 69.2-92.4)100% (5/5, 47.8-100)84.6% (44/52, 71.9-93.1)Pyrotinib86.9% (53/61, 75.8-94.1)71.4% (5/7, 29.0-96.3)85.3% (58/68, 74.6-92.7)Lapatinib80.0% (28/35, 63.1-91.6)100% (1/1, 2.5-100)80.6% (29/36, 64.0-91.8)T-DM182.4% (14/17, 56.6-96.2)100% (3/3, 29.2-100)85.0% (17/20, 62.1-96.8)Other HER2-ADC (except T-DM1)**60.0% (9/15, 32.3-83.7)50.0% (2/4, 6.8-93.2)57.9% (11/19, 33.5-79.8)ORR in pts with tumor types other than BC (N=65)HER2 IHC3+ or IHC2+/ISH+ (N=36)HER2 IHC2+/ISH- or IHC1+ or unknown (N=29)All other tumor types (N=65)% (n/N)38.9% (14/36)31.0% (9/29)35.4% (23/65)ORR was shown as % (n/N, 95% CI) or % (n/N).
Clinical • P1 data • PK/PD data • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 mutation • HER-2 expression • HER-2 underexpression
|
lapatinib • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • Irene (pyrotinib) • Aidixi (disitamab vedotin) • trastuzumab rezetecan (SHR-A1811) • anvatabart opadotin (JNJ-0683) • trastuzumab botidotin (A166) • PF-06804103 • trastuzumab vedotin (MRG002) • trastuzumab envedotin (DP303c) • BAT8001 • TAA013 • DX126-262
1year
Safety, tolerability, pharmacokinetics, and efficacy of SHR-A1811, an antibody-drug conjugate, in patients with advanced HER2-mutant non-small cell lung cancer (NSCLC): a multicenter, open-label, phase 1/2 study (AACR 2023)
SHR-A1811 showed tolerable safety profile and durable antitumor activity in heavily pretreated patients with HER2-mutant NSCLC. Dose expansion at 4.8 mg/kg and 5.6 mg/kg is ongoing to establish the RP2D.
Clinical • P1/2 data • PK/PD data • IO biomarker • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 mutation
|
trastuzumab rezetecan (SHR-A1811)
1year
FUSCC Refractory TNBC Platform Study (FUTURE2.0) (clinicaltrials.gov)
P2, N=120, Not yet recruiting, Fudan University
New P2 trial
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • ER negative • PGR negative
|
Avastin (bevacizumab) • AiRuiKa (camrelizumab) • trastuzumab rezetecan (SHR-A1811)
1year
A Phase Ib/II Study of SHR-A1811 Injection in HER2 Positive Breast Cancer (clinicaltrials.gov)
P2, N=402, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
|
Perjeta (pertuzumab) • Irene (pyrotinib) • albumin-bound paclitaxel • trastuzumab rezetecan (SHR-A1811) • adebrelimab (SHR-1316)
1year
FASCINATE-N: Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (clinicaltrials.gov)
P1/2, N=716, Recruiting, Fudan University | Not yet recruiting --> Recruiting
Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • CD8 (cluster of differentiation 8) • FOXC1 (Forkhead Box C1)
|
Herceptin (trastuzumab) • carboplatin • Perjeta (pertuzumab) • AiRuiKa (camrelizumab) • Irene (pyrotinib) • albumin-bound paclitaxel • cyclophosphamide • letrozole • epirubicin • trastuzumab rezetecan (SHR-A1811) • AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib) • goserelin acetate • adebrelimab (SHR-1316)
over1year
Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2+ Gastric Cancer (clinicaltrials.gov)
P2, N=156, Not yet recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd.
New P2 trial • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
|
capecitabine • oxaliplatin • trastuzumab rezetecan (SHR-A1811)
over1year
SNF Platform Study of HR+/ HER2-advanced Breast Cancer (clinicaltrials.gov)
P2, N=140, Recruiting, Fudan University | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HR positive • HER-2 amplification • HER-2 negative • PGR positive
|
sorafenib • everolimus • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • capecitabine • albumin-bound paclitaxel • fulvestrant • exemestane • trastuzumab rezetecan (SHR-A1811) • AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib) • goserelin acetate • famitinib (SHR 1020)
over1year
A Study of SHR-A1811 Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients (clinicaltrials.gov)
P2, N=61, Not yet recruiting, Shengjing Hospital
New P2 trial
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
|
Irene (pyrotinib) • trastuzumab rezetecan (SHR-A1811)
over1year
SNF Platform Study of HR+/ HER2-advanced Breast Cancer (clinicaltrials.gov)
P2, N=140, Not yet recruiting, Fudan University
New P2 trial • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HR positive • HER-2 amplification • HER-2 negative • PGR positive
|
sorafenib • everolimus • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • capecitabine • albumin-bound paclitaxel • fulvestrant • exemestane • trastuzumab rezetecan (SHR-A1811) • AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib) • goserelin acetate • famitinib (SHR 1020)
Share via
